Ureteral Disease

Categories: Nephrological diseases

Aliases & Classifications for Ureteral Disease

MalaCards integrated aliases for Ureteral Disease:

Name: Ureteral Disease 12 15
Ureteral Diseases 45 74
Ureteral Disorders 44
Disorder of Ureter 74


External Ids:

Disease Ontology 12 DOID:1426
MeSH 45 D014515
NCIt 51 C27148

Summaries for Ureteral Disease

MedlinePlus : 44 Your kidneys make urine by filtering wastes and extra water from your blood. The urine travels from the kidneys to the bladder in two thin tubes called ureters. The ureters are about 8 to 10 inches long. Muscles in the ureter walls tighten and relax to force urine down and away from the kidneys. Small amounts of urine flow from the ureters into the bladder about every 10 to 15 seconds. Sometimes the ureters can become blocked or injured. This can block the flow of urine to the bladder. If urine stands still or backs up the ureter, you may get a urinary tract infections. Doctors diagnose problems with the ureters using different tests. These include urine tests, x-rays, and examination of the ureter with a scope called a cystoscope. Treatment depends on the cause of the problem. It may include medicines and, in severe cases, surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Ureteral Disease, also known as ureteral diseases, is related to vesicoureteral reflux 1 and ureterocele. An important gene associated with Ureteral Disease is SLC3A1 (Solute Carrier Family 3 Member 1), and among its related pathways/superpathways are Pathways in cancer and Mesodermal Commitment Pathway. The drugs Tamsulosin and Morphine have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and smooth muscle, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A urinary system disease that is located in the ureter.

Wikipedia : 77 In human anatomy, the ureters are tubes made of smooth muscle fibers that propel urine from the kidneys... more...

Related Diseases for Ureteral Disease

Diseases related to Ureteral Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 27)
# Related Disease Score Top Affiliating Genes
1 vesicoureteral reflux 1 30.3 C16orf58 MCU PAX2 REN ROBO2 UPK3A
2 ureterocele 11.0
3 hypotonia-cystinuria syndrome 10.2 PREPL SLC3A1 SLC7A9
4 hypertrophic scars 10.2 SMAD2 SMAD3 TGFB1
5 peyronie's disease 10.2 SMAD3 SMAD7 TGFB1
6 hypochondrogenesis 10.2 SMAD2 SMAD3 SMAD7
7 multicystic dysplastic kidney 10.2 PAX2 REN
8 spastic paraplegia 3, autosomal dominant 10.2 CDH1 SMAD2 TGFB1
9 obstructive nephropathy 10.1 REN SMAD2 SMAD3 TGFB1
10 keloids 10.1 SMAD2 SMAD3 SMAD7 TGFB1
11 clear cell adenocarcinoma 10.1 PAX2 SMAD2 SMAD3
12 familial vesicoureteral reflux 10.1 ROBO2 TGFB1
13 inappropriate adh syndrome 10.1 AQP2 REN
14 bladder disease 10.0 CDH1 SLC3A1 SLC7A9 UPK3A
15 ureteral obstruction 10.0 AQP2 BMP7 TGFB1
16 cystinuria 10.0 PREPL SLC3A1 SLC3A2 SLC7A9
17 spondylocarpotarsal synostosis syndrome 9.9 CCN2 SMAD2 SMAD3
18 pauci-immune glomerulonephritis 9.9 BMP7 CCN2 SMAD2
19 pulmonary fibrosis 9.9 CCN2 SMAD3 SMAD7 TGFB1
20 urinary system disease 9.8 AQP2 CCN2 REN TGFB1
21 stiff skin syndrome 9.8 CCN2 TGFB1
22 nephrogenic systemic fibrosis 9.8 CCN2 SMAD2 SMAD3 SMAD7 TGFB1
23 liver cirrhosis 9.8 AQP2 CCN2 REN TGFB1
24 pulmonary fibrosis, idiopathic 9.7 CCN2 CDH1 SMAD2 SMAD3 TGFB1
25 kidney disease 9.4 AQP2 BMP7 CCN2 PAX2 REN TGFB1
26 renal fibrosis 9.2 BMP7 CCN2 CDH1 REN SMAD2 SMAD3
27 urinary tract obstruction 9.0 AQP2 C16orf58 CCN2 CDH1 REN SMAD2

Graphical network of the top 20 diseases related to Ureteral Disease:

Diseases related to Ureteral Disease

Symptoms & Phenotypes for Ureteral Disease

MGI Mouse Phenotypes related to Ureteral Disease:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.33 BMP7 CCN2 CDH1 FN1 MCU PAX2
2 homeostasis/metabolism MP:0005376 10.33 AQP2 CCN2 CDH1 FN1 MCU REN
3 growth/size/body region MP:0005378 10.32 AQP2 BMP7 CCN2 CDH1 FN1 MCU
4 cellular MP:0005384 10.28 CCN2 CDH1 FN1 MCU PAX2 ROBO2
5 behavior/neurological MP:0005386 10.26 AQP2 BMP7 MCU PREPL REN ROBO2
6 mortality/aging MP:0010768 10.24 AQP2 BMP7 CCN2 CDH1 FN1 MCU
7 immune system MP:0005387 10.17 BMP7 CDH1 FN1 REN SLC3A1 SLC3A2
8 digestive/alimentary MP:0005381 10.16 BMP7 CCN2 CDH1 ROBO2 SLC3A2 SMAD2
9 embryo MP:0005380 10.15 BMP7 CCN2 CDH1 FN1 PAX2 SMAD2
10 craniofacial MP:0005382 10.07 BMP7 CCN2 FN1 SMAD2 SMAD3 SMAD7
11 integument MP:0010771 10.06 AQP2 BMP7 CCN2 CDH1 FN1 SMAD2
12 muscle MP:0005369 9.92 FN1 MCU PREPL REN ROBO2 SLC3A1
13 normal MP:0002873 9.76 BMP7 CCN2 CDH1 FN1 REN ROBO2
14 neoplasm MP:0002006 9.73 CDH1 FN1 SLC3A2 SMAD2 SMAD3 TGFB1
15 renal/urinary system MP:0005367 9.65 AQP2 BMP7 PAX2 REN ROBO2 SLC3A1
16 reproductive system MP:0005389 9.36 AQP2 BMP7 CDH1 FN1 PAX2 REN

Drugs & Therapeutics for Ureteral Disease

Drugs for Ureteral Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 106133-20-4 129211
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Nefopam Approved, Investigational Phase 4 13669-70-0
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
Silodosin Approved Phase 4,Phase 2 160970-54-7
Oxycodone Approved, Illicit, Investigational Phase 4,Not Applicable 76-42-6 5284603
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
Sodium Citrate Approved, Investigational Phase 4 68-04-2
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2 7440-70-2 271
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12 Naftopidil Investigational Phase 4,Phase 3 57149-07-2
13 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
14 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
15 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
16 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
18 Calcium, Dietary Phase 4,Phase 3,Phase 2
19 Platelet Aggregation Inhibitors Phase 4,Phase 3
20 calcium channel blockers Phase 4,Phase 3
21 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
22 Antihypertensive Agents Phase 4,Phase 3
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Central Nervous System Depressants Phase 4,Phase 2,Not Applicable
25 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2,Not Applicable
26 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Vasodilator Agents Phase 4,Phase 3
29 Muscarinic Antagonists Phase 4,Not Applicable
30 Cholinergic Antagonists Phase 4,Not Applicable
31 Cholinergic Agents Phase 4,Not Applicable
32 Tolterodine tartrate Phase 4 124937-52-6
33 Narcotics Phase 4,Not Applicable
34 Analgesics, Opioid Phase 4,Not Applicable
35 Cyclooxygenase Inhibitors Phase 4,Not Applicable
36 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Not Applicable
38 Anti-Inflammatory Agents Phase 4,Phase 3,Not Applicable
39 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2
40 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
41 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
42 Ketorolac Tromethamine Phase 4
43 Cytochrome P-450 Enzyme Inhibitors Phase 4
44 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
45 Cyclooxygenase 2 Inhibitors Phase 4,Not Applicable
46 Phosphodiesterase 5 Inhibitors Phase 4
47 Sildenafil Citrate Phase 4 171599-83-0
48 Citrate Phase 4
49 Phosphodiesterase Inhibitors Phase 4
Doxazosin Approved Phase 3 74191-85-8 3157

Interventional clinical trials:

(show top 50) (show all 183)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
2 Treatment of Upper Ureteric Stones Unknown status NCT02469766 Phase 4
3 Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones Unknown status NCT01167062 Phase 4 Tamsulosin Hydrochloride OCAS 0.4 mg
4 The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study Unknown status NCT00489112 Phase 4 Alfuzocine XL 10 mg once a day
5 Naftopidil 75mg for Improving Clearance of Urinary Stones Unknown status NCT02011737 Phase 4 naftopidil 75mg
6 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Completed NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
7 Functional MR Urography Completed NCT00301470 Phase 4
8 Nefopam and Morphine Consumption in the Treatment of Ureteral Calculi Completed NCT00639574 Phase 4 Néfopam
9 Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones Completed NCT01533389 Phase 4 Silodosin;Placebo
10 Tamsulosin for Urolithiasis in the Emergency Dept Completed NCT00382265 Phase 4 tamsulosin
11 Tamsulosin as Adjuvant Treatment Prior to Endoscopic Ureterolithotomy Recruiting NCT03614052 Phase 4 Tamsulosin Hydrochloride 0.4 milligrams;Placebo Oral Tablet
12 Study of Ketorolac Versus Opioid for Pain After Endoscopy Recruiting NCT03888144 Phase 4 Oxycodone;Ketorolac
13 Antibiotic Prophylaxis Before Shock Wave Lithotripsy Recruiting NCT03692715 Phase 4 Ciprofloxacin;Placebo
14 Phosphodiesterase 5 Inhibitors (PDE5i) (Sildenafil) as Medical Expulsive Therapy in Distal Ureteral Stones Active, not recruiting NCT02519153 Phase 4 Sildenafil
15 Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms Enrolling by invitation NCT03799120 Phase 4 Tamsulosin BID
16 Silodosin Versus Tamsulosin for Treatment of Ureteral Stones Terminated NCT02369744 Phase 4 Silodosin;Tamsulosin
17 Celecoxib (Celebrex) in the Management of Acute Renal Colic Withdrawn NCT00304317 Phase 4 celecoxib
18 Alfuzosin for Medical Expulsion Therapy of Ureteral Stones Unknown status NCT00713739 Phase 3 Alfuzosin;nifedipine;doxazosin;prazosin
19 Evaluation of Tamsulosin in the Treatment of Ureteral Stones Completed NCT00151567 Phase 3 Tamsulosin;Placebo
20 Medical Expulsive Therapy for Ureter Stone Using Naftopidil Completed NCT01952314 Phase 3 Naftopidil 75mg;Placebo for Naftopidil;Standard treatment
21 Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi Completed NCT00177086 Phase 3
22 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
23 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
24 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
25 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Recruiting NCT03474107 Phase 3 enfortumab vedotin;docetaxel;vinflunine;paclitaxel
26 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
27 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
28 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
29 Comparison of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction Unknown status NCT01823575 Phase 2
30 Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin Unknown status NCT00478998 Phase 2 Tamsulosin
31 Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy Unknown status NCT00409227 Phase 2 Alpha blocker-alfuzosin;placebo
32 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
33 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2 sunitinib malate
34 Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
35 Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract Unknown status NCT00006111 Phase 2 cisplatin;fluorouracil
36 A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
37 Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in Chronic Strictures of the Ureter Completed NCT00790686 Phase 2
38 Study of Silodosin to Facilitate Passage of Urinary Stones Completed NCT01144949 Phase 2 silodosin;placebo
39 Assessment of Drug-eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation Completed NCT00250406 Phase 2
40 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2 TRC105
41 Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum Completed NCT01426126 Phase 2 Genexol PM
42 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Completed NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
43 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
44 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) Completed NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
45 Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment Completed NCT01031875 Phase 2 pazopanib hydrochloride
46 Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer Completed NCT00792025 Phase 2 sunitinib malate
47 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2 AZD4877
48 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
49 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2 pazopanib hydrochloride
50 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2

Search NIH Clinical Center for Ureteral Disease

Cochrane evidence based reviews: ureteral diseases

Genetic Tests for Ureteral Disease

Anatomical Context for Ureteral Disease

MalaCards organs/tissues related to Ureteral Disease:

Kidney, Testes, Smooth Muscle, Endothelial, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Ureteral Disease:

The Ureter

Publications for Ureteral Disease

Articles related to Ureteral Disease:

# Title Authors Year
In vitro, in vivo, and clinical tests of a novel flexible ureteroscope for the diagnosis and treatment of kidney and ureteral diseases. ( 30182078 )
Reno-ureteral diseases inducing hypertension in children. ( 19480305 )
Extensive dilation of distal ureter for endoscopic treatment of large volume ureteral disease. ( 7869503 )
Ureteroscopy with rigid instruments in the management of distal ureteral disease. ( 6737571 )
Ipsilateral ureteroureterostomy for single ureteral disease in patients with ureteral duplication: a review of 8 years of experience with 16 patients. ( 650746 )
Role of the excretory urogram in the diagnosis of renal and ureteral disease. ( 4479909 )
Transureteroureterostomy in the management of distal ureteral disease. ( 5047409 )

Variations for Ureteral Disease

Expression for Ureteral Disease

Search GEO for disease gene expression data for Ureteral Disease.

Pathways for Ureteral Disease

Pathways related to Ureteral Disease according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1 12.76 CDH1 FN1 SMAD2 SMAD3 TGFB1
Show member pathways
Show member pathways
4 12.28 CDH1 SMAD2 SMAD3 TGFB1
Show member pathways
Show member pathways
12.16 FN1 SLC3A2 SLC7A9 TGFB1
11 11.98 BMP7 SMAD2 SMAD3 TGFB1
12 11.93 FN1 SMAD2 SMAD3 SMAD7 TGFB1
Show member pathways
14 11.85 FN1 SMAD3 TGFB1
15 11.83 FN1 SMAD2 SMAD3 TGFB1
16 11.79 SMAD2 SMAD3 SMAD7 TGFB1
Show member pathways
18 11.69 SMAD2 SMAD3 SMAD7
21 11.65 CDH1 SMAD2 SMAD3
22 11.65 SMAD2 SMAD3 SMAD7 TGFB1
23 11.62 BMP7 SMAD2 SMAD3 TGFB1
Show member pathways
25 11.56 BMP7 CCN2 SMAD7 TGFB1
Show member pathways
11.25 SLC3A1 SLC3A2 SLC7A9
29 11.2 SMAD2 SMAD3 TGFB1
30 11.11 CCN2 SMAD2 SMAD3
31 10.94 SMAD2 SMAD3
32 10.94 BMP7 CCN2 CDH1 FN1 TGFB1
33 10.28 CDH1 FN1 SMAD2 SMAD3 TGFB1

GO Terms for Ureteral Disease

Cellular components related to Ureteral Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.35 AQP2 FN1 SLC3A2 SLC7A9 UPK3A
2 SMAD protein complex GO:0071141 9.16 SMAD2 SMAD3
3 heteromeric SMAD protein complex GO:0071144 8.62 SMAD2 SMAD3
4 plasma membrane GO:0005886 10.03 AQP2 CCN2 CDH1 REN ROBO2 SLC1A7

Biological processes related to Ureteral Disease according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.95 BMP7 CCN2 FN1 SMAD2 SMAD3 TGFB1
2 leukocyte migration GO:0050900 9.94 FN1 SLC3A2 SLC7A9 TGFB1
3 response to estradiol GO:0032355 9.87 BMP7 CCN2 TGFB1
4 response to organic substance GO:0010033 9.86 CDH1 REN TGFB1
5 kidney development GO:0001822 9.86 BMP7 REN ROBO2 UPK3A
6 response to glucose GO:0009749 9.84 CCN2 SMAD2 TGFB1
7 response to wounding GO:0009611 9.84 CCN2 FN1 TGFB1
8 cellular response to transforming growth factor beta stimulus GO:0071560 9.82 SMAD3 SMAD7 TGFB1
9 regulation of MAPK cascade GO:0043408 9.81 BMP7 REN TGFB1
10 transforming growth factor beta receptor signaling pathway GO:0007179 9.81 SMAD2 SMAD3 SMAD7 TGFB1
11 wound healing GO:0042060 9.8 FN1 SMAD2 SMAD3 TGFB1
12 amino acid transport GO:0006865 9.79 SLC3A1 SLC3A2 SLC7A9
13 positive regulation of bone mineralization GO:0030501 9.76 BMP7 SMAD3 TGFB1
14 mesoderm formation GO:0001707 9.75 BMP7 SMAD2 SMAD3
15 positive regulation of protein import into nucleus GO:0042307 9.74 CDH1 SMAD3 TGFB1
16 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.73 SMAD2 SMAD3 SMAD7 TGFB1
17 endoderm development GO:0007492 9.72 SMAD2 SMAD3 TGFB1
18 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.7 PAX2 TGFB1
19 water transport GO:0006833 9.7 AQP2 UPK3A
20 activin receptor signaling pathway GO:0032924 9.7 SMAD2 SMAD3
21 negative regulation of cell-cell adhesion GO:0022408 9.69 CDH1 TGFB1
22 lens fiber cell differentiation GO:0070306 9.68 SMAD3 TGFB1
23 pathway-restricted SMAD protein phosphorylation GO:0060389 9.68 SMAD7 TGFB1
24 nodal signaling pathway GO:0038092 9.68 SMAD2 SMAD3
25 primary miRNA processing GO:0031053 9.68 SMAD2 SMAD3
26 response to cholesterol GO:0070723 9.67 SMAD2 TGFB1
27 salivary gland morphogenesis GO:0007435 9.67 BMP7 TGFB1
28 SMAD protein signal transduction GO:0060395 9.67 BMP7 SMAD2 SMAD3 TGFB1
29 embryonic foregut morphogenesis GO:0048617 9.66 SMAD2 SMAD3
30 pericardium development GO:0060039 9.65 SMAD2 SMAD3
31 response to laminar fluid shear stress GO:0034616 9.65 SMAD7 TGFB1
32 metanephric collecting duct development GO:0072205 9.63 AQP2 PAX2
33 common-partner SMAD protein phosphorylation GO:0007182 9.63 SMAD2 TGFB1
34 embryonic pattern specification GO:0009880 9.63 BMP7 SMAD2 SMAD3
35 endocardial cushion formation GO:0003272 9.62 BMP7 ROBO2
36 positive regulation of epithelial to mesenchymal transition GO:0010718 9.62 BMP7 SMAD2 SMAD3 TGFB1
37 positive regulation of extracellular matrix assembly GO:1901203 9.61 SMAD3 TGFB1
38 L-cystine transport GO:0015811 9.6 SLC3A1 SLC7A9
39 regulation of striated muscle tissue development GO:0016202 9.59 SMAD3 TGFB1
40 mesonephros development GO:0001823 9.58 BMP7 PAX2 REN
41 evasion or tolerance of host defenses by virus GO:0019049 9.54 SMAD3 TGFB1
42 paraxial mesoderm morphogenesis GO:0048340 9.52 SMAD2 SMAD3
43 SMAD protein complex assembly GO:0007183 9.43 SMAD2 SMAD3 TGFB1
44 L-alpha-amino acid transmembrane transport GO:1902475 9.39 SLC7A9
45 regulation of binding GO:0051098 9.33 SMAD2 SMAD3 TGFB1
46 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.26 SMAD2 SMAD3 SMAD7 TGFB1
47 ureteric bud development GO:0001657 9.1 BMP7 ROBO2 SMAD2 SMAD3 SMAD7 TGFB1
48 positive regulation of transcription, DNA-templated GO:0045893 10.08 BMP7 CDH1 PAX2 SMAD2 SMAD3 TGFB1

Molecular functions related to Ureteral Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 beta-catenin binding GO:0008013 9.65 CDH1 SMAD3 SMAD7
2 collagen binding GO:0005518 9.61 FN1 SMAD3 SMAD7
3 enhancer binding GO:0035326 9.52 SMAD2 SMAD3
4 neutral amino acid transmembrane transporter activity GO:0015175 9.51 SLC3A2 SLC7A9
5 co-SMAD binding GO:0070410 9.49 SMAD2 SMAD3
6 I-SMAD binding GO:0070411 9.46 SMAD2 SMAD7
7 primary miRNA binding GO:0070878 9.4 SMAD2 SMAD3
8 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.37 SMAD2 SMAD3
9 amino acid transmembrane transporter activity GO:0015171 9.32 SLC3A1 SLC7A9
10 L-cystine transmembrane transporter activity GO:0015184 9.26 SLC3A1 SLC7A9
11 type I transforming growth factor beta receptor binding GO:0034713 9.13 SMAD2 SMAD7 TGFB1
12 transforming growth factor beta receptor binding GO:0005160 8.92 BMP7 SMAD2 SMAD3 TGFB1
13 protein binding GO:0005515 10.11 AQP2 BMP7 CCN2 CDH1 FN1 MCU

Sources for Ureteral Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
33 HPO
34 ICD10
35 ICD10 via Orphanet
39 LifeMap
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
56 Novoseek
59 OMIM via Orphanet
63 PubMed
71 SNOMED-CT via Orphanet
73 Tocris
75 UMLS via Orphanet
Loading form....